Does neoadjuvant chemotherapy affect postoperative complication rates in elderly patients treated with radical cystectomy for bladder cancer?

Authors

null

Nozomi Hayakawa

Department of Urology, Keio University School of Medicine, Tokyo, Japan

Nozomi Hayakawa , Eiji Kikuchi , Ryuichi Mizuno , Mototsugu Oya , Kimiharu Takamatsu

Organizations

Department of Urology, Keio University School of Medicine, Tokyo, Japan, Keio University Hospital, Tokyo, Japan

Research Funding

Other

Background: Although the survival benefit of neoadjuvant chemotherapy (NAC) in bladder cancer patients receiving radical cystectomy (RC) has been established, the NAC associated complication rate is not well-known, especially in elderly patients. Methods: We identified 427 patients who had undergone RC for clinical TanyN0M0 bladder cancer from 2005 to 2015 at our 7 institutions. Among them, 118 (27.6%) were treated with gemcitabine and cisplatin (GC)-NAC. The details of the complication rate during and after RC were recorded according to the Clavien-Dindo classification. We evaluated the association between the complication rate for RC with NAC and patient age. Results: Overall, 60 (14.0%), 306 (71.7%), and 61 (14.3%) patients were < 60, 60-79, and ≥ 80 years old, respectively. Overall, 190 (44.5%) patients had some kind of postoperative complication and there was no difference in the postoperative complication rate between the NAC and non-NAC groups (37.3% vs 47.2%: p = 0.065). However, the incidence rate of post-operative ileus in the NAC group was 9.3%, which was significantly lower than that in the non-NAC group (19.1%, p = 0.013). Sixteen (26.7%), 93 (30.4%) and 9 (14.8%) patients in the < 60, 60-79, and ≥ 80 age groups, respectively, received GC-NAC. Among patients < 60 years old, the complication rates for post-operative ileus, pyelonephritis and wound infection were 12.5%, 18.8%, and 0% in the NAC group, which were not significantly different from those in the non-NAC group (9.1%, 6.8%, and 13.6%, respectively). Among 60-79 year-old patients, the corresponding complication rates were 8.6%, 11.8%, and 9.7% in the NAC group, which were not significantly different from those in the non-NAC group (17.8%, 9.9%, and 9.4%, respectively). Among patients ≥ 80 years old, the rates were 11.1%, 11.1%, and 33.3% in the NAC group, which were not significantly different from those in the non-NAC group (28.8%, 11.5%, and 13.5%, respectively). Furthermore, in patients treated with GC-NAC, no association was observed in the complication rates among patients < 60 years, 60-79 years, and ≥ 80 years old. Conclusions: NAC could be provided safely at the time of RC regardless of patient age.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr e16526)

DOI

10.1200/JCO.2018.36.15_suppl.e16526

Abstract #

e16526

Abstract Disclosures